Compare Avantis International Small Cap Value ETF (AVDV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Merck & Co., Inc. — how do they compare? Avantis International Small Cap Value ETF trades at $110.25, while Merck & Co., Inc. trades at $132.92 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Avantis International Small Cap Value ETF pays none. Which is the better fit depends on your goals.
| AVDV | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $131.84 |
52-Week Low | $83.89 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $110.51, up 0.96% today, with a bullish technical outlook from moving averages but caution from oscillators like the 6-day RSI at 87.64 indicating overbought conditions. Recent news highlights strong 2026 performance, with international small-cap value strategies gaining attention. The stock shows support near $108-$109 and resistance at $110.
The outlook remains positive due to momentum in international small-cap value, though overbought signals and reliance on commodity sectors pose risks. Investors should weigh the ETF's diversification benefits against potential volatility from global economic shifts.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
